Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This study found that the p.E402K mutation in the KRT86 gene is a hotspot in Chinese patients with monilethrix, and treatment with 5% topical minoxidil significantly improved hair density and quality.

This study demonstrated that an ethanol extract of Connarus semidecandrus Jack showed potential anti-androgenic alopecia effects in a testosterone-induced model, suggesting a possible treatment option for hair loss.

This review of legal cases found that 5α-reductase inhibitors, alleged to cause sexual, mental, and physical side effects, have led to numerous lawsuits with increasing litigation expected in the future.

In this study, 5-aminolevulinic acid photodynamic therapy did not improve hair growth in patients with androgenetic alopecia but was safe and slightly reduced scalp sebum secretion.

This study found that a topical herbal solution significantly increased hair diameter and density in men with androgenetic alopecia compared to minoxidil after 36 weeks of treatment.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

This preliminary study found that Melandrium firmum extract may promote hair growth and inhibit 5α-reductase, suggesting potential as a candidate for treating androgenetic alopecia.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

This abstract outlines the current understanding of cutaneous squamous cell carcinoma (cSCC), identifying it as the second most common non-melanoma skin cancer with risk factors like UV exposure and immunosuppression. It highlights cSCC's potential to metastasize and become fatal, affecting 2%-5% of in situ cases.

In this study, researchers found a statistically significant increase in reports of suicidality and depression associated with finasteride use, especially in younger individuals, whereas dutasteride showed no significant signal for suicidality and a weaker signal for depression.

In this retrospective study from five Colombian cities, researchers detailed the clinical characteristics of 562 alopecia areata patients, noting that multiple plaques and the patchy subtype were common, with steroid injections frequently used as treatment.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.

In this case study, researchers reported that a patient with plaque alopecia areata experienced complete and sustained hair regrowth after treatment with 5-Fluorouracil and Bleomycin via microinfusion of medicines, despite initial cutaneous atrophy caused by intralesional corticosteroid therapy.

In this study, fenugreek seed extract showed significant androgenic and spermatogenic effects in male rats, likely through inhibiting testosterone metabolism, without impacting cardiovascular health.

This study investigates the potential of onion extract as a treatment for androgenetic alopecia by using in silico and ADME/T analyses to examine how active compounds from onions interact with the 5-alpha-reductase enzyme.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

This case study reported that 5% minoxidil solution effectively promoted hair growth and resulted in generalized hypertrichosis in a 7-year-old with Trichorhinophalangeal syndrome type I.

This study explored a new dutasteride nanocarrier for alopecia therapy, concluding that ingredient concentration is key to achieving the optimal particle size, stability, and skin permeation for extended drug release.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

This study reports the development of a microemulsion using Momordica charantia extract, which demonstrated strong antioxidant and 5α-reductase inhibitory activity, potentially aiding hair loss management. The microemulsion was stable over 12 weeks, suggesting its future potential for cosmetic or pharmacological applications.

This case report describes a 36-year-old Pakistani phenotypic female diagnosed with 46,XY 5-alpha-reductase deficiency, highlighting that such disorders of sexual development can manifest with symptoms like obesity, hirsutism, and amenorrhea later in life due to unique circumstances.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.